Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

BACKGROUND: Peptide-based vaccination is a rational option for immunotherapy of prostate cancer. In this first-in-man phase I/II study, we assessed the safety, tolerability and immunological impact of a synthetic long peptide vaccine targeting Ras homolog gene family member C (RhoC) in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuhmacher, Juliane, Heidu, Sonja, Balchen, Torben, Richardson, Jennifer Rebecca, Schmeltz, Camilla, Sonne, Jesper, Schweiker, Jonas, Rammensee, Hans-Georg, Thor Straten, Per, Røder, Martin Andreas, Brasso, Klaus, Gouttefangeas, Cécile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662471/
https://www.ncbi.nlm.nih.gov/pubmed/33184050
http://dx.doi.org/10.1136/jitc-2020-001157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662471/
https://www.ncbi.nlm.nih.gov/pubmed/33184050
http://dx.doi.org/10.1136/jitc-2020-001157

Ejemplares similares